Investigation of roxadustat compliance and related influencing factors in patients undergoing maintenance peritoneal dialysis_West China Medical Journal

Authors：

LIU Xia , PU Li , ZHOU Xueli , LI Kuo , HE Xueqin , QIN Min ,  MA Dengyan

Department of Nephrology, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

MA Dengyan, Email: mdy5104@163.com

Keywords：

Maintenance peritoneal dialysis; Roxadustat; Medication compliance; Renal anemia

DOI：

10.7507/1002-0179.202106031

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the status of roxadustat in patients undergoing maintenance peritoneal dialysis and analyze the factors affecting drug compliance. Methods Patients with renal anemia undergoing maintenance peritoneal dialysis in West China Hospital of Sichuan University from July 2020 to March 2021 were selected. All patients took roxadustat orally. According to the medication compliance, the patients were divided into good compliance group and poor compliance group. The general information questionnaire and Morisky Medication Adherence Scale-8 (MMAS-8) were used to investigate and analyze the included patients, and their clinical examination indexes were collected. Results A total of 100 patients were included, Including 39 cases (39%) in the good compliance group and 61 cases (61%) in the poor compliance group. The average score of medication compliance of roxadustat was 5.19±1.72. Logistic regression analysis showed that drug cognition [odds ratio (OR)=0.099, 95% confidence interval (CI) (0.027, 0.365), P=0.001], medication troubles/complex protocol [OR=5.330, 95%CI (1.567, 18.132), P=0.007], and adverse drug reactions [OR=5.453, 95%CI (1.619, 18.368), P=0.006] were factors affecting patient compliance. Hemoglobin in the good compliance group was lower than that in the poor compliance group (Z=−2.259, P=0.024); there was no significant difference in other clinical examination indexes (P>0.05). Conclusions The overall compliance of oral roxadustat in maintenance peritoneal dialysis patients is poor, and the corresponding follow-up management system should be improved. Nurses should provide comprehensive and systematic medication guidance to patients, encourage them to fully understand the clinical manifestations, treatment schemes and prognosis of renal anemia, clarify the time, dose, possible adverse reactions and mitigation methods of roxadustat, etc., and help them to treat the disease with correct cognition and attitude, so as to improve their drug compliance.

Citation： LIU Xia, PU Li, ZHOU Xueli, LI Kuo, HE Xueqin, QIN Min, MA Dengyan. Investigation of roxadustat compliance and related influencing factors in patients undergoing maintenance peritoneal dialysis. West China Medical Journal, 2021, 36(9): 1205-1209. doi: 10.7507/1002-0179.202106031 Copy

1.	Chen Y, Fang W, Gu L, et al. The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study. Int Urol Nephrol, 2018, 50(1): 167-171.
2.	Wang AY, Brimble KS, Brunier G, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients partⅠ- assessment and management of various cardiovascular risk factors. Perit Dial Int, 2015, 35(4): 379-387.
3.	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识 (2018 修订版). 中华肾脏病杂志, 2018, 34(11): 860-866.
4.	陈孟华, 田娜. 腹膜透析患者的贫血诊治现状. 中国血液净化, 2020, 19(9): 581-584.
5.	Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol, 2019, 15(12): 731-732.
6.	张喜梅. 罗沙司他治疗慢性肾脏病非透析贫血患者的 meta 分析. 衡阳: 南华大学, 2020.
7.	孟彤, 张灵健, 沈智文, 等. 临床药物依从性评价的研究进展. 医药导报, 2021, 40(4): 466-471.
8.	Chen L, He JX, Chen YY, et al. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Ren Fail, 2018, 40(1): 15-21.
9.	许卫华, 王奇, 梁伟雄. 慢性疾病患者服药依从性测量量表的编制. 中国慢性病预防与控制, 2008, 16(6): 558-560, 567.
10.	吴凡, 赵金霞, 王天晟, 等. 中文版 MMAS-8 测量类风湿关节炎患者用药依从性的信效度分析. 中国药房, 2018, 29(2): 263-268.
11.	中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南. 中华医学杂志, 2021, 101(20): 1463-1502.
12.	杨永, 杨连招, 胡艳宁, 等. 老年高血压病人未按时服药影响因素的质性研究. 护理研究, 2016, 30(13): 1635-1638.
13.	李欣芹, 王文秀. 健康促进模式教育对消化性溃疡门诊患者用药依从性和疗效的影响. 河北医学, 2016, 22(5): 790-792.
14.	Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol, 2015, 67(10): 2557-2568.
15.	周雅萍, 李凯. 治疗肾性贫血新药罗沙司他. 药物评价研究, 2018, 41(9): 1743-1748.
16.	王培培, 吴涛. 口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察. 山东医药, 2020, 60(33): 73-75.
17.	许海燕, 胡厚源, 李敏. 药物依从障碍国外研究述评. 中国药房, 2018, 29(19): 2723-2727.
18.	Coburn BW, Bendlin KA, Sayles H, et al. Allopurinol medication adherence as a mediator of optimal outcomes in gout management. J Clin Rheumatol, 2017, 23(6): 317-323.
19.	Byun DW, Moon SH, Kim T, et al. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. J Bone Miner Metab, 2019, 37(3): 563-572.
20.	李伟超. 应用罗沙司他治疗肾性贫血对患者微炎症因子的影响. 中国实用医药, 2021, 16(2): 123-125.
21.	陈豫闽, 刘俊英, 贾国强, 等. 罗沙司他在维持性腹膜透析患者肾性贫血治疗中的应用效果. 广东医学, 2021, 42(2): 216-220.

1. Chen Y, Fang W, Gu L, et al. The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study. Int Urol Nephrol, 2018, 50(1): 167-171.
2. Wang AY, Brimble KS, Brunier G, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients partⅠ- assessment and management of various cardiovascular risk factors. Perit Dial Int, 2015, 35(4): 379-387.
3. 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识 (2018 修订版). 中华肾脏病杂志, 2018, 34(11): 860-866.
4. 陈孟华, 田娜. 腹膜透析患者的贫血诊治现状. 中国血液净化, 2020, 19(9): 581-584.
5. Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol, 2019, 15(12): 731-732.
6. 张喜梅. 罗沙司他治疗慢性肾脏病非透析贫血患者的 meta 分析. 衡阳: 南华大学, 2020.
7. 孟彤, 张灵健, 沈智文, 等. 临床药物依从性评价的研究进展. 医药导报, 2021, 40(4): 466-471.
8. Chen L, He JX, Chen YY, et al. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Ren Fail, 2018, 40(1): 15-21.
9. 许卫华, 王奇, 梁伟雄. 慢性疾病患者服药依从性测量量表的编制. 中国慢性病预防与控制, 2008, 16(6): 558-560, 567.
10. 吴凡, 赵金霞, 王天晟, 等. 中文版 MMAS-8 测量类风湿关节炎患者用药依从性的信效度分析. 中国药房, 2018, 29(2): 263-268.
11. 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南. 中华医学杂志, 2021, 101(20): 1463-1502.
12. 杨永, 杨连招, 胡艳宁, 等. 老年高血压病人未按时服药影响因素的质性研究. 护理研究, 2016, 30(13): 1635-1638.
13. 李欣芹, 王文秀. 健康促进模式教育对消化性溃疡门诊患者用药依从性和疗效的影响. 河北医学, 2016, 22(5): 790-792.
14. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol, 2015, 67(10): 2557-2568.
15. 周雅萍, 李凯. 治疗肾性贫血新药罗沙司他. 药物评价研究, 2018, 41(9): 1743-1748.
16. 王培培, 吴涛. 口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察. 山东医药, 2020, 60(33): 73-75.
17. 许海燕, 胡厚源, 李敏. 药物依从障碍国外研究述评. 中国药房, 2018, 29(19): 2723-2727.
18. Coburn BW, Bendlin KA, Sayles H, et al. Allopurinol medication adherence as a mediator of optimal outcomes in gout management. J Clin Rheumatol, 2017, 23(6): 317-323.
19. Byun DW, Moon SH, Kim T, et al. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. J Bone Miner Metab, 2019, 37(3): 563-572.
20. 李伟超. 应用罗沙司他治疗肾性贫血对患者微炎症因子的影响. 中国实用医药, 2021, 16(2): 123-125.
21. 陈豫闽, 刘俊英, 贾国强, 等. 罗沙司他在维持性腹膜透析患者肾性贫血治疗中的应用效果. 广东医学, 2021, 42(2): 216-220.

West China Medical Journal

Investigation of roxadustat compliance and related influencing factors in patients undergoing maintenance peritoneal dialysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content